BioHelix's mission is to improve the quality of healthcare through the development of simple molecular diagnostic tests for the near patient setting, wherein rapid solutions are necessary for prompt medical intervention.  

By combining its proprietary isothermal Helicase Dependent Amplification (HDA) technology with an instrument-free detection device, the company's IsoAmp® assays enable more clinical laboratories to perform molecular diagnostic tests with random-access flexibility and minimum capital expenditure.

Through its strong R&D capability and partnerships with IVD industry leaders, the company aims to provide simple and cost-effective solutions for enabling molecular diagnostics to be practiced in middle-tier hospital labs, at the point-of-care, and in the future, for personalized medicine.